These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 35183803)

  • 1. Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma.
    Lyu X; Tsui YM; Ho DW; Ng IO
    Cell Mol Gastroenterol Hepatol; 2022; 13(6):1611-1624. PubMed ID: 35183803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma.
    Wu X; Li J; Gassa A; Buchner D; Alakus H; Dong Q; Ren N; Liu M; Odenthal M; Stippel D; Bruns C; Zhao Y; Wahba R
    Int J Biol Sci; 2020; 16(9):1551-1562. PubMed ID: 32226301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine.
    Moldogazieva NT; Zavadskiy SP; Terentiev AA
    Cancer Genomics Proteomics; 2021; 18(3 Suppl):369-383. PubMed ID: 33994362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA mutation analysis: advances in its application for early diagnosis of hepatocellular carcinoma and therapeutic efficacy monitoring.
    Yang J; Lin N; Niu M; Yin B
    Aging (Albany NY); 2024 Jul; 16(14):11460-11474. PubMed ID: 39033781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.
    Weng J; Atyah M; Zhou C; Ren N
    Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA/circulating tumor cells and the applicability in different causes induced hepatocellular carcinoma.
    Li X; Wang H; Li T; Wang L; Wu X; Liu J; Xu Y; Wei W
    Curr Probl Cancer; 2020 Apr; 44(2):100516. PubMed ID: 31836136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
    Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
    Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining tissue and circulating tumor DNA increases the detection rate of a CTNNB1 mutation in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Weber B; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    BMC Cancer; 2021 Apr; 21(1):376. PubMed ID: 33827453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid biopsy using cell-free DNA in the early diagnosis of hepatocellular carcinoma.
    Hu S; Liu Y; Yang Q; Chen L; Chai H; Xiao M; Qi C; Qiu W
    Invest New Drugs; 2023 Jun; 41(3):532-538. PubMed ID: 37099161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid biopsy derived circulating tumor cells and circulating tumor DNA as novel biomarkers in hepatocellular carcinoma.
    Temraz S; Nasr R; Mukherji D; Kreidieh F; Shamseddine A
    Expert Rev Mol Diagn; 2022 May; 22(5):507-518. PubMed ID: 35758097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma-Literature Review.
    Kopystecka A; Patryn R; Leśniewska M; Budzyńska J; Kozioł I
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status of ctDNA in precision oncology for hepatocellular carcinoma.
    Li Y; Zheng Y; Wu L; Li J; Ji J; Yu Q; Dai W; Feng J; Wu J; Guo C
    J Exp Clin Cancer Res; 2021 Apr; 40(1):140. PubMed ID: 33902698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy Outcomes.
    Mezzalira S; De Mattia E; Guardascione M; Dalle Fratte C; Cecchin E; Toffoli G
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31694149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized circulating tumor DNA in patients with hepatocellular carcinoma: a pilot study.
    Pommergaard HC; Yde CW; Ahlborn LB; Andersen CL; Henriksen TV; Hasselby JP; Rostved AA; Sørensen CL; Rohrberg KS; Nielsen FC; Rasmussen A
    Mol Biol Rep; 2022 Feb; 49(2):1609-1616. PubMed ID: 34811635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning-based genome-wide interrogation of somatic copy number aberrations in circulating tumor DNA for early detection of hepatocellular carcinoma.
    Tao K; Bian Z; Zhang Q; Guo X; Yin C; Wang Y; Zhou K; Wan S; Shi M; Bao D; Yang C; Xing J
    EBioMedicine; 2020 Jun; 56():102811. PubMed ID: 32512514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA.
    Ye Q; Ling S; Zheng S; Xu X
    Mol Cancer; 2019 Jul; 18(1):114. PubMed ID: 31269959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection.
    Jin C; Liu X; Zheng W; Su L; Liu Y; Guo X; Gu X; Li H; Xu B; Wang G; Yu J; Zhang Q; Bao D; Wan S; Xu F; Lai X; Liu J; Xing J
    Mol Oncol; 2021 Sep; 15(9):2377-2389. PubMed ID: 34133846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor DNA Clinical Applications in Hepatocellular Carcinoma: Current Trends and Future Perspectives.
    Bardol T; Pageaux GP; Assenat E; Alix-Panabières C
    Clin Chem; 2024 Jan; 70(1):33-48. PubMed ID: 37962158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.
    Xu RH; Wei W; Krawczyk M; Wang W; Luo H; Flagg K; Yi S; Shi W; Quan Q; Li K; Zheng L; Zhang H; Caughey BA; Zhao Q; Hou J; Zhang R; Xu Y; Cai H; Li G; Hou R; Zhong Z; Lin D; Fu X; Zhu J; Duan Y; Yu M; Ying B; Zhang W; Wang J; Zhang E; Zhang C; Li O; Guo R; Carter H; Zhu JK; Hao X; Zhang K
    Nat Mater; 2017 Nov; 16(11):1155-1161. PubMed ID: 29035356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preferred end coordinates and somatic variants as signatures of circulating tumor DNA associated with hepatocellular carcinoma.
    Jiang P; Sun K; Tong YK; Cheng SH; Cheng THT; Heung MMS; Wong J; Wong VWS; Chan HLY; Chan KCA; Lo YMD; Chiu RWK
    Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10925-E10933. PubMed ID: 30373822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.